IL17A and psoriasis: The tumor necrosis factor-alpha (TNF-α)/IL-23/IL-17A axis plays a key role in induction and progression of psoriasis; thus, biological drugs against TNFα/IL-23/IL-17A have good therapeutic efficacy [109].